Obradović Aleksandar, Raičević Marija, Joksimović Milko
Institute for Public Health of Montenegro, 81000 Podgorica, Montenegro.
Vaccines (Basel). 2025 Mar 6;13(3):278. doi: 10.3390/vaccines13030278.
: The Delta variant of SARS-CoV-2 dominated Montenegro from July 2020 until early 2022, when Omicron took over. COVID-19 vaccination began on 20 February 2021, two months later than in the EU. The study aimed to investigate the impact of vaccination on mortality rates in Montenegro during Delta's predominance. : A descriptive study was conducted using data from the Montenegrin Institute of Public Health COVID-19 database, the Population Electronic Immunization Register, which provides data for all administrated COVID-19 vaccines in Montenegro, and EUROSTAT mortality data. : COVID-19 accounted for 17.8% of total deaths in Montenegro during the period of study. Crude mortality rate among unvaccinated was almost four times higher compared to those who received at least one vaccine dose. Inactivated vaccines were predominantly administered to those aged 60 and over, while RNA vaccines were mainly given to those under 60. The median interval between the last vaccine dose and death was significantly higher for vector vaccines compared to inactivated vaccines. : The delayed start of vaccination and limited vaccine choices in Montenegro likely contributed to prolonged high mortality due to COVID-19. Our findings reveal disparities in vaccine distribution and effectiveness, highlighting the need for timely and equitable access to effective vaccines, especially for vulnerable populations. : The study underscores the importance of prompt vaccine distribution and the option to choose vaccine types in building public trust and reducing mortality rates. It emphasizes the need for strengthening global mechanisms COVAX and continuing educational activities to address vaccine hesitancy and ensure equitable access to effective vaccines.
2020年7月至2022年初,新冠病毒的德尔塔变异株在黑山占据主导地位,之后被奥密克戎变异株取代。新冠疫苗接种于2021年2月20日开始,比欧盟晚两个月。该研究旨在调查在德尔塔变异株占主导期间,疫苗接种对黑山死亡率的影响。:采用黑山公共卫生研究所新冠病毒数据库、人口电子免疫登记册(提供黑山所有接种的新冠疫苗数据)以及欧盟统计局死亡率数据进行描述性研究。:在研究期间,新冠病毒导致的死亡占黑山总死亡人数的17.8%。未接种疫苗者的粗死亡率几乎是至少接种一剂疫苗者的四倍。灭活疫苗主要接种给60岁及以上人群,而RNA疫苗主要接种给60岁以下人群。与灭活疫苗相比,载体疫苗最后一剂接种至死亡的中位间隔时间明显更长。:黑山疫苗接种开始延迟且疫苗选择有限,可能导致新冠病毒造成的高死亡率持续时间延长。我们的研究结果揭示了疫苗分配和有效性方面的差异,凸显了及时、公平地获取有效疫苗的必要性,尤其是对于弱势群体。:该研究强调了迅速分发疫苗以及选择疫苗类型对于建立公众信任和降低死亡率的重要性。它强调需要加强全球疫苗免疫联盟机制并持续开展教育活动,以解决疫苗犹豫问题并确保公平获取有效疫苗。